- Conditions
- Glioblastoma
- Interventions
- Modified Atkins Ketogenic Diet
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 259
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Cancer
- Interventions
- TPI 287
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- karenitecin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
- Interventions
- methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
- Conditions
- Central Nervous System Tumor
- Interventions
- tozuleristide, Canvas imaging system, Surgical resection of tumor
- Drug · Device · Procedure
- Lead sponsor
- John Yu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
- Interventions
- Niraparib, Temozolomide
- Drug
- Lead sponsor
- Ivy Brain Tumor Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Interventions
- C134
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Brain and Central Nervous System Tumors, Prostate Cancer
- Interventions
- everolimus, gefitinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Interventions
- Toca 511 vector, Toca FC
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Detroit, Michigan + 5 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Primary Hepatocellular Carcinoma, Adult Subependymoma, Advanced Adult Primary Liver Cancer, Advanced Malignant Mesothelioma, Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Malignant Mesothelioma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, Stage III Esophageal Cancer, Stage III Pancreatic Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma, Brain Neoplasms
- Interventions
- NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
- Device · Procedure · Genetic
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • St Louis, Missouri
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- fenretinide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
- Interventions
- Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
- Drug · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
- Conditions
- Brain Tumor, Recurrent, Glioblastoma Multiforme
- Interventions
- Photon Radiosurgery System (Intrabeam)
- Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 2 Years to 32 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
- Interventions
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
- Combination Product
- Lead sponsor
- Shayan Moosa, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioblastoma Multiforme, Healthy Volunteers
- Interventions
- GBM Patients, Normal Controls
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
- Interventions
- Posaconazole Pill
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
- Interventions
- TVI-Brain-1
- Biological
- Lead sponsor
- TVAX Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, carmustine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- procarbazine hydrochloride
- Drug
- Lead sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
- Interventions
- CT-322, irinotecan hydrochloride
- Drug
- Lead sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 10
- States / cities
- La Jolla, California • Lexington, Kentucky • Boston, Massachusetts + 7 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Not listed
- Lead sponsor
- Guoqiang Yu
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
- Interventions
- CONVIVO system, Conventional histologic evaluation
- Diagnostic Test · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire